Kensey Nash Exits Embolic Protection To Focus R&D Cash On Biomaterials
This article was originally published in The Gray Sheet
Executive Summary
Kensey Nash's discontinuation of its embolic protection device business will free-up R&D resources for its biomaterials division, the firm says